Home > Healthcare > Pharmaceuticals > Finished Drug Form > Central Nervous System Therapeutics Market

Central Nervous System Therapeutics Market Trends

Report ID: GMI6097
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Central Nervous System Therapeutics Market Trends

The market is experiencing several notable trends that are shaping its progression and development. Some key trends in the industry includes increasing advancements in precision medicine, increasing focus on developing therapeutics that not only alleviate symptoms but also target the underlying mechanisms of CNS disorders, rise of digital therapeutics and remote monitoring, integration of artificial intelligence in healthcare, and focus on combination therapies.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Central nervous system (CNS) therapeutics industry was worth USD 110.4 billion in 2022 and is projected to reach USD 238.8 billion by 2032 owing to the high prevalence of CNS disorders across the globe

The antidepressant drug type segment held 25.5% of the market share in 2022 and is poised to expand at 8.3% CAGR by 2032 attributed to the rising prevalence of mental health disorders globally.

North America CNS therapeutics industry size is anticipated to record 7.9% CAGR and reach USD 113.3 billion by 2032 attributed to the rising focus on technological advancements in healthcare in the region

Some of the prominent market players are Biogen, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Merck & Co., Astra Zeneca, Shire PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and Pfizer, Inc.